|
|
Parnell Pharmaceuticals Holdings
|
| General Information |
| Business: |
We are a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. We currently market five products for companion animals and production animals in 14 countries and augment our pharmaceutical products with our proprietary iKAM and mySYNCH® software platforms. These innovative technology solutions are designed to enhance the quality of life or performance of animals, while driving our customers’ operational efficiency and profitability. We believe our value-added solutions help establish us as a business partner with our customers rather than only as a commodity provider, differentiating us from our competitors. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
55 |
Founded: |
2009 |
|
| Contact Information |
| Address: |
Unit 4 Century Estate, 476 Gardeners Rd, Alexandria, NSW, 2015, Australia |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 9.3 mil (last 12 months) |
|
| Net Income: |
$ -8.0 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
PARN |
| Shares (millions): |
5.0 |
| Price Range: |
$10.00 - $10.00 |
| Est.$ Volume |
$ 50.0 mil |
| Manager / Joint Managers |
Jefferies/ Piper Jaffray |
| Co Managers |
JMP Securities/ Ladenburg Thalmann/ Geller Biopharm |
| Expected to Trade |
6/18/2014 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
